Current Hepatitis Reports

, Volume 4, Issue 2, pp 68–74

Antiviral therapy in the HCV-coinfected patient with HIV and/or HBV

  • James S. Park
  • Neeraj Saraf
  • Douglas T. Dieterich

DOI: 10.1007/s11901-005-0017-1

Cite this article as:
Park, J.S., Saraf, N. & Dieterich, D.T. Curr hepatitis rep (2005) 4: 68. doi:10.1007/s11901-005-0017-1


Coinfection of hepatitis C virus (HCV)-infected patients with HIV or hepatitis B virus (HBV) is common because of shared modes of transmission. Coinfection with HBV or HIV has been shown to accelerate the course of chronic hepatitis C and facilitate progression to cirrhosis and hepatocellular carcinoma. Currently, the combination of pegylated interferon and ribavirin is the best available treatment in HIV/HCV-coinfected patients. The optimal treatment of HCV in persons with HBV coinfection has not been defined but may include pegylated interferon alpha plus ribavirin initially, followed by oral anti-HBV agents, such as lamivudine or adefovir, or both.

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • James S. Park
  • Neeraj Saraf
  • Douglas T. Dieterich
    • 1
  1. 1.Division of Liver DiseasesMount Sinai Medical CenterNew YorkUSA

Personalised recommendations